Fatal marrow aplasia after treatment with carbimazole.
作者信息
BURRELL C D
出版信息
Br Med J. 1956 Jun 23;1(4981):1456-7. doi: 10.1136/bmj.1.4981.1456.
Abstract
摘要
相似文献
1
Fatal marrow aplasia after treatment with carbimazole.卡比马唑治疗后发生致命性骨髓再生障碍。
Br Med J. 1956 Jun 23;1(4981):1456-7. doi: 10.1136/bmj.1.4981.1456.
2
Fatal case of marrow aplasia after treatment with carbimazole; the effect of ACTH.卡比马唑治疗后发生再生障碍性贫血的致命病例；促肾上腺皮质激素的作用。
Br Med J. 1954 Feb 13;1(4858):364-5. doi: 10.1136/bmj.1.4858.364.
3
Fatal agranulocytosis during carbimazole therapy.卡比马唑治疗期间发生的致命性粒细胞缺乏症。
Lancet. 1957 Feb 9;272(6963):303. doi: 10.1016/s0140-6736(57)90363-x.
4
Toxicity of the antithyroid drug carbimazole.抗甲状腺药物卡比马唑的毒性
J Clin Endocrinol Metab. 1956 Mar;16(3):391-6. doi: 10.1210/jcem-16-3-391.
5
Agranulocytosis from carbimazole.卡比马唑所致粒细胞缺乏症
Br Med J. 1955 Jul 23;2(4933):246. doi: 10.1136/bmj.2.4933.246.
6
The low toxicity of carbimazole; a survey of 1,046 patients.卡比马唑的低毒性：1046例患者的调查
Br Med J. 1956 Jun 23;1(4981):1453-6. doi: 10.1136/bmj.1.4981.1453.
7
Agranulocytosis in a patient treated with carbimazole.一名接受卡比马唑治疗的患者出现粒细胞缺乏症。
Lancet. 1954 Feb 20;266(6808):396. doi: 10.1016/s0140-6736(54)90931-9.
8
[Bone marrow aplasia caused by synthetic antithyroid agents].
An Med Interna. 2004 Jan;21(1):48-9. doi: 10.4321/s0212-71992004000100017.
9
Antenatal carbimazole and choanal atresia: a new embryopathy.产前使用卡比马唑与后鼻孔闭锁：一种新的胚胎病。
Arch Otolaryngol Head Neck Surg. 2006 Sep;132(9):1009-11. doi: 10.1001/archotol.132.9.1009.
10
Change from propylthiouracil to carbimazole proves fatal.从丙硫氧嘧啶换用卡比马唑被证明是致命的。
N Z Med J. 2001 Dec 14;114(1145):553.
引用本文的文献
1
Clinical characteristics of antithyroid drug-induced aplastic anemia cases over the past 30 years.30 年来抗甲状腺药物致再生障碍性贫血病例的临床特点。
Front Endocrinol (Lausanne). 2023 Jan 27;14:1064723. doi: 10.3389/fendo.2023.1064723. eCollection 2023.
2
Carbimazole (neo-mercazole) in thyrotoxicosis--a review of sixty patients.卡比马唑（新唛卡唑）治疗甲状腺毒症——60例患者的回顾
Ulster Med J. 1959 Nov 1;28(2):148-63.
3
Pharmacokinetics of methimazole in humans.
Klin Wochenschr. 1985 Dec 2;63(23):1212-7. doi: 10.1007/BF01733780.
4
Cross sensitivity to antithyroid drugs.对抗甲状腺药物的交叉敏感性。
BMJ. 1989 May 6;298(6682):1253. doi: 10.1136/bmj.298.6682.1253-b.
5
Agranulocytosis and antithyroid drugs.粒细胞缺乏症与抗甲状腺药物
West J Med. 1977 May;126(5):339-43.
本文引用的文献
1
The low toxicity of carbimazole; a survey of 1,046 patients.卡比马唑的低毒性：1046例患者的调查
Br Med J. 1956 Jun 23;1(4981):1453-6. doi: 10.1136/bmj.1.4981.1453.
2
Toxicity of the antithyroid drug carbimazole.抗甲状腺药物卡比马唑的毒性
J Clin Endocrinol Metab. 1956 Mar;16(3):391-6. doi: 10.1210/jcem-16-3-391.
3
Antithyroid activity and toxicity of mercazole and neo-mercazole.甲巯咪唑和新甲巯咪唑的抗甲状腺活性及毒性
J Clin Endocrinol Metab. 1954 Oct;14(10):1230-44. doi: 10.1210/jcem-14-10-1230.
4
Agranulocytosis in a patient treated with carbimazole.一名接受卡比马唑治疗的患者出现粒细胞缺乏症。
Lancet. 1954 Feb 20;266(6808):396. doi: 10.1016/s0140-6736(54)90931-9.
5
Fatal case of marrow aplasia after treatment with carbimazole; the effect of ACTH.卡比马唑治疗后发生再生障碍性贫血的致命病例；促肾上腺皮质激素的作用。
Br Med J. 1954 Feb 13;1(4858):364-5. doi: 10.1136/bmj.1.4858.364.
6
Clinical experience with a new antithyroid drug: 2-carbethoxythio-1-methylglyoxaline.
J Clin Endocrinol Metab. 1953 Nov;13(11):1305-11. doi: 10.1210/jcem-13-11-1305.
Zotero 插件